1. |
Strategies to fight multidrug resistant TB |
|
Inpharma Weekly,
Volume &NA;,
Issue 1333,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1333,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1333,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Amlodipine in CAD: potential for cost savings in Sweden |
|
Inpharma Weekly,
Volume &NA;,
Issue 1333,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Acid suppressants still used in PUD afterH. pylorieradication |
|
Inpharma Weekly,
Volume &NA;,
Issue 1333,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
TMC 125: next-generation NNRTI has potent anti-HIV activity |
|
Inpharma Weekly,
Volume &NA;,
Issue 1333,
2002,
Page 7-8
Ed Susman,
Preview
|
|
摘要:
TMC 125, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) demonstrated potent anti-HIV activity in two studies presented at the 9th Conference on Retroviruses and Opportunistic Infections [Seattle, US; February 2002]. In the first study, TMC 125 demonstrated significant antiviral activity in patients with NNRTI-resistant HIV infection who were failing their current NNRTI-containing regimen.1In the second study, involving treatment-naive patients, monotherapy with TMC 125 resulted in reductions in viral load that were comparable to those achieved with a 5-drug combination in a previous study involving similar patients.2
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
Protease inhibitors exhibit promising anti-angiogenic activity |
|
Inpharma Weekly,
Volume &NA;,
Issue 1333,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1333,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1333,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Valdecoxib effective against postoperative pain |
|
Inpharma Weekly,
Volume &NA;,
Issue 1333,
2002,
Page 11-12
Bruce Sylvester,
Preview
|
|
摘要:
Valdecoxib ['Bextra'], a second-generation cyclo-oxygenase (COX)-2 inhibitor, is effective in controlling pain following knee replacement surgery, according to a study presented at the 69th Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) [Dallas, US; February 2002].1In this study, treatment with valdecoxib significantly reduced morphine use, compared with placebo, and was well tolerated, with a high level of patient satisfaction reported. In a separate study published in theAmerican Journal of Therapeutics,valdecoxib demonstrated superiority over rofecoxib ['Vioxx'] in the treatment of postoperative dental pain.2
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|